ABOUT THE JOURNAL   

The bimonthly journal Biomeditsinskaya Khimiya (former Problems of Medical Chemistry) is published since 1955. It covers all major aspects of Biomedical chemistry and related areas, including, transcriptomics, proteomics, metabolomics, bioinformatics, enzymology, molecular biology, biochemical pharmacology, molecular and cellular medicine, clinical biochemistry. The Journal also publishes review articles. Submitted manuscripts should be written in Russian (see the Russian version for details).
In 2007-2022 the part of manuscripts was published in English in Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, ISSN 1990-7508.

EDITORIAL POLICY   

The journal publishes papers covering all aspects of biomedical chemistry and related disciplines, including genomics, transcriptomics, proteomics, metabolomics, bioinformatics, enzymology, molecular biology, biochemical pharmacology, molecular and cellular medicine, clinical biochemistry, etc.

In cooperation with a new publishing project aimed at methodological aspects of biomedical research, all methodological articles (original and review articles) should be sent directly to the editorial board of Biomedical Chemistry: Research and Methods.

Journal Section Policy
Free submissionIndexingPeer-reviewed
EXPERIMENTAL RESEARCH
This section publishes the results of classical experimental as well as computational studies.
CLINICAL AND DIAGNOSTIC RESEARCH
Clinical works performed on biological material obtained from patients and/or healthy volunteers must include a mandatory statement that all participants gave consent to participate in the study and to use their bio-samples. Such information must be placed in the section “ETHICAL STANDARDS”.
REVIEWS
The Journal of Biomedical Chemistry accepts reviews both ordered by the editorial board and proposed by the authors. In the latter case, the editorial board reserves the right to reject the submitted review without expert evaluation, if the editors or the members of editorial board decide that at the moment the journal is not interested in publishing the review on the proposed topic. It is advisable submit first a tentative title of the review and a detailed summary via e-mail of 300-600 words. This will help to evaluate the purpose of the review, the subject area and the central idea of the review, the target readership, the presence in the review of data obtained by the authors personally, and any other aspects.
SHORT COMMUNICATIONS
Short communications are works of high priority (as a rule, no more than 1.5-2 thousand words), containing no more than 2-3 illustrations (or tables). The term of publication of short communications is usually 2-4 months after acceptance for publication.
MISCELLANEOUS
In this section, messages from the Editorial Board are printed, as well as author’s materials expressing the author’s personal view point on a scientific event or publication on the subject of the journal, letters to the Editorial Board, as well as Chronicles of congresses, conventions and conferences (not later than 2 months after the event). The decision to publish the submitted materials is made by the Editorial Board. Rejection of publication cannot be questioned.

REVIEWING   

The Journal of Biomedical Chemistry uses an external peer review for all incoming materials. Highly qualified specialists with experience in a particular scientific area and having publications on topics directly related to the reviewed work are involved as reviewers. Members of the editorial board can also act as reviewers for works related to their scientific interests. In addition, at the stage of initial selection in obvious cases members of the editorial board make a collegial decision on the compliance of the proposed material with the profile of the journal.

Materials submitted for publication are reviewed by at least two reviewers. It is recommended that reviewers follow to the Guidelines for Reviewers. The maximum time limit for submitting a reviewer report is no more than one month after acceptance of reviewer invitation. In case of different viewpoints of reviewers, the decision about the subsequent fate of submitted materials is made by the editorial board on the basis of reviewer’s reports. The paper can also be sent for additional reviewing. The authors have the right to disagree with the reviewer’s opinion and provide the editorial board with a reasoned response to the review. All correspondence between the reviewers and the author is conducted exclusively through the editorial board. The data of the reviewers remain strictly confidential to the authors.

When resolving any disputes that arose in the process of reviewing the article, the decision of the editorial board is final.

The article sent to the authors for revision must be returned in the corrected form within two months. The authors should also attach a cover letter, giving all point-to-point to the referee comments and explains all the changes.

The final decision on publication of the revised paper is made by the editorial board.

Manuscript processing

  • A newly submitted manuscript is registered at the moment of receipt in electronic form with the notification of the author of receipt.
  • Within one week, the Editorial Board finds appropriate reviewers for this manuscript or the manuscript is rejected by the Editorial Board due to its inconsistency with the journal policy.
  • The manuscript is submitted for reviewing to the assigned reviewers. If reviewing is not performed within one month, a new reviewer is assigned. The maximum period of reviewing is set by the editorial board at three months. During the summer vacation period (July-August), the established review deadlines are not applicable.
  • Reviewer reports are sent to the author in any case:
    — In case of a positive review, the manuscript is passed to the editorial board to prepare it for publication.
    — If the manuscript needs to be revised, the review is sent to the author together with all the reviewer’s comments and suggestions.
    — In the case of a negative review of the manuscript, a review with a motivated rejection is sent to corresponding author.
  • After receiving the results of the review, the author prepares the necessary materials. – If the manuscript is revised, the author prepares a revised version of the manuscript and a response to the reviewer (up to two months). A revised version of the manuscript is sent for a second review.
  • A manuscript that has received positive reviewer reports is approved for publication by the editor-in-chief or the editorial board meeting and is sent for further processing.

EDITORIAL ETHICS   

Copyright

Authors who publish articles in the Journal of Biomedical Chemistry agree with to the following:
  1. The authors retain the copyright and grant the journal the right to first publish the work, which, after 12 months of publication, is automatically licensed under the Creative Commons Attribution License, which allows others to distribute the work in question with mandatory credit to the authors of the original work and the original publication in the Journal of Biomedical Chemistry.
  2. The authors retain the right to make separate contractual arrangements for the non-exclusive distribution of the version of the work as published here (e.g., posting it in an institutional repository, publishing it in a book), with a link to its original publication in Biomedical Chemistry.
  3. Authors have the right to post their work online (e.g., in an institutional repository or personal website) before and during the Biomedical Chemistry journal review process, as this can lead to productive discussion and more references to the work (The Effect of Open Access).

Protection of personal data

The names and email addresses entered on the Journal of Biomedical Chemistry website will be used solely for the purposes designated by this journal and will not be used for any other purpose or shared with other individuals or organizations.

PUBLISHING ETHICS 

The section has been prepared by Non-for-profit Partnership National Electronic-Information Consortium (NEICON).

The Publication Ethics and Publication Malpractice Statement of the journal Biomeditsinskaya Khimiya are based on the Committee on Publication Ethics (COPE) Code of Conduct guidelines available at www.publicationethics.org and requirements for peer-reviewed medical journals , elaborated by the Elsevier Publishing House (in accordance with international ethical rules of scientific publications).

1. Introduction

1.1. The publication in a peer reviewed learned journal, serves many purposes outside of simple communication. It is a building block in the development of a coherent and respected network of knowledge. For all these reasons and more it is important to lay down standards of expected ethical behaviour by all parties involved in the act of publishing: the author, the journal editor, the peer reviewer, the publisher and the society for society-owned or sponsored journal: Biomeditsinskaya Khimiya.

1.2. Publisher has a supporting, investing and nurturing role in the scholarly communication process but is also ultimately responsible for ensuring that best practice is followed in its publications.

1.3. Publisher takes its duties of guardianship over the scholarly record extremely seriously. Our journal programs record «the minutes of science» and we recognize our responsibilities as the keeper of those «minutes» in all our policies not least the ethical guidelines that we have here adopted.

2. Duties of Editors

2.1. Publication decision
The Editor of a learned Biomeditsinskaya Khimiya is solely and independently responsible for deciding which of the articles submitted to the journal should be published, often working on conjunction with the relevant society (for society-owned or sponsored journals). The validation of the work in question and its importance to researchers and readers must always underwrite such decisions. The Editor may be guided by the policies of the Biomeditsinskaya Khimiya journal’s editorial board and constrained by such legal requirements as shall then be in force regarding libel, copyright infringement and plagiarism. The editor may confer with other editors or reviewers (or society officers) in making this decision.

2.2. Fair play
An editor should evaluate manuscripts for their intellectual content without regard to race, gender, sexual orientation, religious belief, ethnic origin, citizenship, or political philosophy of the authors.

2.3. Confidentiality
The editor and any editorial staff of Biomeditsinskaya Khimiya must not disclose any information about a submitted manuscript to anyone other than the corresponding author, reviewers, potential reviewers, other editorial advisers, and the publisher, as appropriate.

2.4. Disclosure and Conflicts of interest

2.4.1. Unpublished materials disclosed in a submitted manuscript must not be used in an editor’s own research without the express written consent of the author. Privileged information or ideas obtained through peer review must be kept confidential and not used for personal advantage.

2.4.2. Editors should recuse themselves (i.e. should ask a co-editor, associate editor or other member of the editorial board instead to review and consider) from considering manuscripts in which they have conflicts of interest resulting from competitive, collaborative, or other relationships or connections with any of the authors, companies, or (possibly) institutions connected to the papers.

2.5. Vigilance over published record
An editor presented with convincing evidence that the substance or conclusions of a published paper are erroneous should coordinate with the publisher (and/or society) to promote the prompt publication of a correction, retraction, expression of concern, or other note, as may be relevant.

2.6.Involvement and cooperation in investigations
An editor should take reasonably responsive measures when ethical complaints have been presented concerning a submitted manuscript or published paper, in conjunction with the publisher (or society). Such measures will generally include contacting the author of the manuscript or paper and giving due consideration of the respective complaint or claims made, but may also include further communications to the relevant institutions and research bodies.

3. Duties of Reviewers

3.1. Contribution to Editorial Decisions
Peer review assists the editor in making editorial decisions and through the editorial communications with the author may also assist the author in improving the paper. Peer review is an essential component of formal scholarly communication, and lies at the heart of the scientific method. Publisher shares the view of many that all scholars who wish to contribute to publications have an obligation to do a fair share of reviewing.

3.2. Promptness
Any selected referee who feels unqualified to review the research reported in a manuscript or knows that its prompt review will be impossible should notify the editor of Biomeditsinskaya Khimiya and excuse himself from the review process.

3.3. Confidentiality
Any manuscripts received for review must be treated as confidential documents. They must not be shown to or discussed with others except as authorised by the editor.

3.4. Standard and objectivity
Reviews should be conducted objectively. Personal criticism of the author is inappropriate. Referees should express their views clearly with supporting arguments.

3.5. Acknowledgement of Sources – Reviewers should identify relevant published work that has not been cited by the authors. Any statement that an observation, derivation, or argument had been previously reported should be accompanied by the relevant citation. A reviewer should also call to the editor’s attention any substantial similarity or overlap between the manuscript under consideration and any other published paper of which they have personal knowledge.

3.6. Disclosure and Conflict of Interest

3.6.1. Unpublished materials disclosed in a submitted manuscript must not be used in a reviewer’s own research without the express written consent of the author. Privileged information or ideas obtained through peer review must be kept confidential and not used for personal advantage.

3.6.2. Reviewers should not consider manuscripts in which they have conflicts of interest resulting from competitive, collaborative, or other relationships or connections with any of the authors, companies, or institutions connected to the papers.

4. Duties of Authors

4.1. Reporting standards

4.1.1. Authors of reports of original research should present an accurate account of the work performed as well as an objective discussion of its significance. Underlying data should be represented accurately in the paper. A paper should contain sufficient detail and references to permit others to replicate the work. Fraudulent or knowingly inaccurate statements constitute unethical behaviour and are unacceptable.

4.1.2. Review and professional publication articles should also be accurate and objective, and editorial ‘opinion’ works should be clearly identified as such.

4.2. Data Access and Retention
Authors may be asked to provide the raw data in connection with a paper for editorial review, and should be prepared to provide public access to such data (consistent with the ALPSP-STM Statement on Data and Databases), if practicable, and should in any event be prepared to retain such data for a reasonable time after publication.

4.3. Originality and Plagiarism

4.3.1. The authors should ensure that they have written entirely original works, and if the authors have used the work and/or words of others, this has been appropriately cited or quoted.

4.3.2. Plagiarism takes many forms, from ‘passing off’ another’s paper as the author’s own paper, to copying or paraphrasing substantial parts of another’s paper (without attribution), to claiming results from research conducted by others. Plagiarism in all its forms constitutes unethical publishing behaviour and is unacceptable.

4.4. Multiple, Redundant or Concurrent Publication

4.4.1. An author should not in general publish manuscripts describing essentially the same research in more than one journal of primary publication. Submitting the same manuscript to more than one journal concurrently constitutes unethical publishing behaviour and is unacceptable.

4.4.2. In general, an author should not submit for consideration in another journal a previously published paper.

4.4.3. Publication of some kinds of articles (eg, clinical guidelines, translations) in more than one journal is sometimes justifiable, provided certain conditions are met. The authors and editors of the journals concerned must agree to the secondary publication, which must reflect the same data and interpretation of the primary document. The primary reference must be cited in the secondary publication. Further detail on acceptable forms of secondary publication can be found at www.icmje.org.

4.5. Acknowledgement of Sources
Proper acknowledgment of the work of others must always be given. Authors should cite publications that have been influential in determining the nature of the reported work. Information obtained privately, as in conversation, correspondence, or discussion with third parties, must not be used or reported without explicit, written permission from the source. Information obtained in the course of confidential services, such as refereeing manuscripts or grant applications, must not be used without the explicit written permission of the author of the work involved in these services.

4.6. Authorship of the Paper

4.6.1. Authorship should be limited to those who have made a significant contribution to the conception, design, execution, or interpretation of the reported study. All those who have made significant contributions should be listed as co-authors. Where there are others who have participated in certain substantive aspects of the research project, they should be acknowledged or listed as contributors.

4.6.2. The corresponding author should ensure that all appropriate co-authors and no inappropriate co-authors are included on the paper, and that all co-authors have seen and approved the final version of the paper and have agreed to its submission for publication.

4.7. Hazards and Human or Animal Subjects

4.7.1. If the work involves chemicals, procedures or equipment that have any unusual hazards inherent in their use, the author must clearly identify these in the manuscript.

4.7.2. If the work involves the use of animal or human subjects, the author should ensure that the manuscript contains a statement that all procedures were performed in compliance with relevant laws and institutional guidelines and that the appropriate institutional committee(s) have approved them. Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

4.8. Disclosure and Conflicts of Interest

4.8.1. All authors should disclose in their manuscript any financial or other substantive conflict of interest that might be construed to influence the results or interpretation of their manuscript. All sources of financial support for the project should be disclosed.

4.8.2. Examples of potential conflicts of interest which should be disclosed include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Potential conflicts of interest should be disclosed at the earliest possible stage.

4.9. Fundamental errors in published works – When an author discovers a significant error or inaccuracy in a published work, it is the author’s obligation to promptly notify the editor of Biomeditsinskaya Khimiya journal and cooperate with Publisher to retract or correct the paper, If the editor or the publisher learn from a third party that a published work contains a significant error, it is the obligation of the author to promptly retract or correct the paper.

5. Duties of the Publisher (and if relevant, Society)

5.1. Publisher should adopt policies and procedures that support editors, reviewers and authors of Biomeditsinskaya Khimiya in performing their ethical duties under these ethics guidelines. The publisher should ensure that the potential for advertising or reprint revenue has no impact or influence on editorial decisions.

5.2. The publisher should support Biomeditsinskaya Khimiya journal editors in the review of complaints raised concerning ethical issues and help communications with other journals and/or publishers where this is useful to editors.

5.3. Publisher should develop codes of practice and inculcate industry standards for best practice on ethical matters, errors and retractions.

5.4. Publisher should provide specialized legal review and counsel if necessary.